Neoadjuvant and adjuvant hormone therapy for prostate cancer

World Journal of Urology

Volumn 18, Issue 3, 2000, Pages 179-182

  Zlotta, Alexandre R ^a   Schulman, Claude C ^a  

^a ERASME HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

ADJUVANT CHEMOTHERAPY; HUMAN; MALE; PROSTATE TUMOR; PROSTATECTOMY; REVIEW;

ANTINEOPLASTIC AGENTS, HORMONAL; CHEMOTHERAPY, ADJUVANT; HUMANS; MALE; PROSTATECTOMY; PROSTATIC NEOPLASMS;

EID: 0034208001     PISSN: 07244983     EISSN: None     Source Type: Journal    
DOI: 10.1007/s003450000119     Document Type: Article

References (25)

1. Arcangeli G, Saracino B, Micheli A, D'Angelo L, Pansadoro V, Crucian! E, Marchetti P (1998) Radiotherapy with or without androgen deprivation in the treatment of localized adenocarcinoma of the prostate. Am J Clin Oncol 2: I -5
2. Aus G, Abrahamsson PA, Ahlgren G, Hugosson J, Lundberg S, Schain M, Schelin S, Pedersen K (1998) Hormonal treatment before radical prostatectomy: a 3-year follow-up. J Urol 159: 2013-2016
3. Bartelink H, Rubens RD, Schueren E van der, Sylvester R (1997) Hormonal therapy prolongs survival in irradiated locally advanced breast cancer: a European Organization for Research and Treatment of Cancer randomized phase III trial. J Clin Oncol 15: 207-215
4. Bolla M, Gonzalez D, Warde P, Dubois JB, Mirimanoff RO, Storme G, Bernier J, Kuten A, Sternberg C, Gil T, Collette L, Pierart M (1997) Improvement survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 337: 295-300
5. Catalona WJ, Smith DS, RatlifTTL, Basler JW (1993) Detection of organ confined prostate cancer is increased through prostate-specific antigen-based screening. JAMA 270: 948
6. Early Breast Cancer Trialists" Collaborative Group(1992) Systemic treatment of early breast cancer by hormonal, cytotoxic or immune therapy. Lancet 339: 1-14
7. Epstein JI, Partin AW, Sauvageot J, Walsh PC (1996) Prediction of progression following radical prostatectomy: a multivariate analysis of 721 men with long-term follow-up. Am J Surg Pathol 20: 286-292
8. Gleave ME, Goldenberg SL, Jones ES, et al (1996) Biochemical and pathological effects of 8 months of neoadjuvant androgen withdrawal therapy before radical prostatectomy in patients with locally confined prostate cancer. J Urol 155: 213-219
9. Klotz LH, Goldenberg SL, Buillock M, Srigley J, Jewett MA, Mador D, Fradet Y, Barkin J, Chin J, Paquin JM, Lapalante S (1997) Neoadjuvant androgen ablation prior to radical prostatectomy (CUOG P-92): 24-month post-treatment PSA results (abstract 1045). Br J Urol 80 [Suppl 2]: 266 10.
10. Lawton CA, Winter K, Byhardt R, Sause WT, Hanks GE, Russell AH, Rotman M, Porter A, McGowan DG, DelRowe JD, Pilepich MV (1997) Androgen suppression plus radiation versus radiation alone for patients with Dl (pN + ) adenocar-cinoma of the prostate (results based on a national prospective randomized trial, RTOG 85-31). Radiation Therapy Oncology Group. Int J Radiât Oncol Biol Phys 38: 931 939
11. Löwe [JA. Lieberman SF (1997) Disease recurrence and progression in untreated pathologic stage T3 prostate cancer: selecting the patient for adjuvant therapy. .1 Urol 158: 1452 1456
12. Meyer F, Moore L, Bairati I, Lacombe L. Tetu B, Fradet Y (1999) Neoadjuvant hormonal therapy before radical prostatectomy and risk of prostate specific antigen failure. J Urol 162: 2024-2028
13. Partin AW, Kattan MW, Subong EN, Walsh PC, Wojno KJ, Oesterling JE, Scardino PT, Pearson JD (1997) Combination of prostate-specific antigen, clinical stage and Gleason score to predict pathological stage of localized prostate cancer. A multiinstitutional update. JAMA 277: 1445
14. Pound CR. Partin AW, Epstein JI, Walsh PC (1997) Prostatespecific antigen after anatomic radical retropubic prostatectomy: patterns of recurrence and cancer control. Urol Clin North Am 24: 395-406
15. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD. Walsh PC (1999) Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281: 15911597
16. Schulman CC, Wildschutz T, Zlotta AR (1997) Neoadjuvant hormonal treatment prior to radical prostatectomy: facts and open questions. Eur Urol 32 [Suppl 3]: 4147
17. Smith DM, Murphy WM (1994) Histologie changes in prostatic carcinomas treated with leuprolide (luteinizing hormonereleasing hormone effect): distinction from poor tumor differentiation. Cancer 73: 1472-1477
18. Soloway M, Sharifi R, Wajsman Z, et al (1997) Radical prostatectomy alone vs radical prostatectomy preceded by androgen blockade in cT2b prostate cancer - 24 month results. J Urol 157: A619
19. Tetu B, Shigley JR, Boivin JC, et al (1991) Effect of combination endocrine therapy (LHRH agonist and flutamide) on normal prostate and prostate adenocarcinoma. A histopathologic and immunohistochemical study. Am J Pathol 15: 111-120
20. Vaillancourt L, Tetu B, Fradet Y, Dupont A, Gomez J, Cusan L, Suburu ER, Diamond P, Candas B, Labrie F (1996) Effects of neoadjuvant endocrine therapy (combined androgen blockade) on normal prostate and prostatic carcinoma. Am J Surg Pathol 20: 1
21. Wirth M, Frohmüller H, Marx F, Bollen M, Thiess M (1997) Randomized multicenter trial on adjuvant flutamide therapy in locally advanced prostate cancer after radical surgery (abstract 1033). Br J Urol 80 [Suppl 2]: 263
22. Wirth M, Frohmüller H, Marx F, Bolten M, Theiss M (1997) Adjuvant anliandrogenic ireatment after radical prostatectomy in stage C prostate cancer - preliminary results of a randomized controlled multicenter trial (abstract 1308). J Urol 157 [Suppl]: 335
23. Witjes WPJ, Schulman CC, Debruyne FMJ (1997) Preliminary results of a prospective randomized study comparing radical prostatectomy versus radical prostatectomy associated with neoadjuvant hormonal combination therapy in T23 NO MO prostatic carcinoma. The European Study Group on Neoadjuvant Treatment of Prostate Cancer. Urology 49: 65-69
24. Zietman AL, Prince EA, Nakfoor BM, Shipley WU (1997) Neoadjuvant androgen suppression with radiation in the management of locally advanced adenocarcinoma of the prostate: experimental and clinical results. Urology 49 [Suppl 3A]: 74-83
25. Zincke H, Bergstrahl EJ, Larson-Keller JJ, Farrow GM, Myers RP. Lieber MM, Barrett DM, Rife CC, Gonchoroff NJ (1992) Stage Dl prostate cancer treated by radical prostatectomy and adjuvant hormonal treatment: evidence for favorable survival in patients with DNA diploid tumors. Cancer 70 [Suppl]: 311-323